Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187202 | 0.82 | GPR119 (0.41) | CHRM2HSD11B1DPP4 | |
| SCHEMBL20187200 | 0.82 | GPR119 (0.41) | CHRM2HSD11B1DPP4 | |
| SCHEMBL9934829 | 0.78 | CHRM2 (0.40) | CHRM2EPHX2HSD11B1DPP4DPP8 | |
| SCHEMBL9934831 | 0.78 | CHRM2 (0.40) | CHRM2EPHX2HSD11B1DPP4DPP8 | |
| SCHEMBL5634920 | 0.72 | EPHX2 (0.57) | CHRM2EPHX2HSD11B1 | |
| SCHEMBL661359 | 0.71 | HSD11B1 (0.51) | HSD11B1 | |
| SCHEMBL18983925 | 0.69 | CHRM2 (0.43) | CHRM2EPHX2 | |
| SCHEMBL17558315 | 0.69 | CHRM2 (0.43) | CHRM2EPHX2 | |
| SCHEMBL19514124 | 0.69 | CHRM2 (0.44) | CHRM2EPHX2HSD11B1 | |
| SCHEMBL18983754 | 0.66 | CHRM2 (0.43) | CHRM2EPHX2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3317279-B1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA-ROCHE INC. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | CHRM2 3315/4885EPHX2 4810/4885HSD11B1 1067/4885 |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | CHRM2 3315/4885EPHX2 4810/4885HSD11B1 1067/4885 |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | CHRM2 3315/4885EPHX2 4810/4885HSD11B1 1067/4885 |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | CHRM2 3315/4885EPHX2 4810/4885HSD11B1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.